白蛋白结合型紫杉醇治疗晚期实体恶性肿瘤的效果观察

Observation on the effect of albumin binding paclitaxel in the treatment of advanced solid malignancy

目的:研究用白蛋白结合型紫杉醇治疗晚期实体恶性肿瘤的效果。方法:选择近年来江苏省无锡市人民医院肿瘤科收治的104例晚期实体恶性肿瘤患者作为研究对象。用白蛋白结合型紫杉醇对这些患者进行治疗,然后观察其近期疗效及用药后发生不良反应的情况。结果:治疗后,这104例患者病情的客观缓解率(ORR)为15.38%,其病情的控制率(DCR)为63.46%,其中位的无进展生存时间(PFS)和总生存时间(OS)分别为5个月(95%CI为2.3~5.6)和10.8个月(95%CI为8.7~12.1)。这104例患者用药后发生的血液学不良反应主要是白细胞和中性粒细胞减少、红细胞减少及血小板减少,其发生的非血液学不良反应主要是周围神经毒性反应、乏力、纳差、粒缺性发热等。用药后,这104例患者中仅有2例患者因出现明显的骨髓抑制而更换其他化疗方案。结论:用白蛋白结合型紫杉醇对晚期实体恶性肿瘤患者进行治疗能提高其近期疗效和对化疗的耐受性。

Objective:To study the efficacy of albumin-bound paclitaxel in the treatment of advanced solid malignancies.Methods:104 patients with advanced solid malignancy admitted to the Oncology department of Wuxi People’s Hospital in recent years were selected as the research objects.These patients were treated with albumin-bound paclitaxel,and the short-term efficacy and adverse reactions were observed.Results:After treatment,the objective remission rate(ORR)and control rate(DCR)of the 104 patients were 15.38%and 63.46%,respectively,and the progression-free survival time(PFS)and total survival time(OS)were 5 months(95%CI,2.3~5.6)and 10.8 months(95%CI,8.7~12.1),respectively.The hematological adverse reactions of these 104 patients were mainly leukopenia,neutropenia,erythrocytopenia and thrombocytopenia,and the non-hematological adverse reactions were mainly peripheral neurotoxic reactions,fatigue,poor appetite,and granulocytopenia fever.After treatment,only 2 of the 104 patients switched to other chemotherapy regiments due to significant bone marrow suppression.Conclusion:Treatment with albumin-bound paclitaxel in patients with advanced solid malignancy can improve its short-term efficacy and chemotherapy tolerance.